Annexon, Inc. (ANNX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$176.2M
Cash & Equivalents
$46.8M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$950M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-31 | Phase3 Readout | — |
| 2026-12-31 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Parti... | PHASE3 | Active Not Recruiting | 659 |
| NCT07020819 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barr... | PHASE3 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.